Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)

被引：0

作者：

Barragan-Carrillo, R. ^{[1
]}

Zengin, Z. B. ^{[1
]}

Dizman, N. ^{[2
]}

Ebrahimi, H. ^{[1
]}

Meza, L. A. ^{[1
]}

Jaime-Casas, S. ^{[2
]}

Li, X. ^{[2
]}

Dorff, T. B. ^{[2
]}

Hsu, J. ^{[1
]}

Salgia, N. ^{[3
]}

Chehrazi-Raffle, A. ^{[2
]}

Tripathi, A. ^{[1
]}

Castro, D. ^{[2
]}

Mercier, B. ^{[2
]}

Caporaso, G. ^{[4
]}

Lee, K. ^{[4
]}

Pal, S. K. ^{[2
]}

机构：

[1] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA

[2] City Hope Comprehens Canc Ctr, Med Oncol & Expt Therapeut, Duarte, CA USA

[3] Roswell Pk Comprehens Canc Ctr, Dept Immunol, Buffalo, NY USA

[4] TGen Translat Genom Res Inst, Dept Biol Sci, Phoenix, AZ USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1792

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1699P

引用

页码：S1018 / S1018

页数：1

共 50 条

[1] Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC)
Dizman, Nazli
Ebrahimi, Hedyeh
Barragan-Carrillo, Regina
Meza, Luis A.
Bergerot, Paulo
Dorff, Tanya
Hsu, JoAnn
Zengin, Zeynep
Castro, Daniela
Chehrazi-Raffle, Alex
Triphathi, Abhishek
Trent, Jeffrey
Takahashi, Motomichi
Oka, Kentaro
Higashi, Seiya
Caporaso, Gregory
Lee, Keehoon
Pal, Sumanta K.
ONCOLOGIST, 2024, 29 : S6 - S6
[2] Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC)
Dizman, Nazli
Ebrahimi, Hedyeh
Carrillo, Regina Barragan
Meza, Luis A.
Bergerot, Paulo Gustavo
Dorff, Tanya B.
Hsu, Joann
Zengin, Zeynep Busra
Castro, Daniela V.
Chehrazi-Raffle, Alex
Tripathi, Abhishek
Trent, Jeffrey M.
Takahashi, Motomichi
Oka, Kentaro
Higashi, Seiya
Caporaso, Gregory
Lee, Keehoon
Pal, Sumanta Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Impact of Latino ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC)
Carrillo, Regina Barragan
Dizman, Nazli
Ebrahimi, Hedyeh
Meza, Luis A.
Bergerot, Paulo Gustavo
Dorff, Tanya B.
Hsu, Joann
Zengin, Zeynep Busra
Salgia, Nicholas
Chehrazi-Raffle, Alex
Tripathi, Abhishek
Castro, Daniela V.
Mercier, Benjamin
Caporaso, Gregory
Lee, Keehoon
Pal, Sumanta Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Impact of Latino Ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC)
Barragan-Carrillo, Regina
ONCOLOGIST, 2024, 29 : S10 - S10
[5] Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial
Ebrahimi, Hedyeh
Meza, Luis A.
Lee, Keehoon
Malhotra, Jasnoor
Alcantara, Marice
Zengin, Zeynep Busra
Dizman, Nazli
Govindarajan, Ameish
Hsu, Joann
Llamas-Quitiquit, Marian
Chawla, Neal Shiv
Castro, Daniela V.
Mercier, Benjamin D.
Liu, Sandy
Chehrazi-Raffle, Alex
Dorff, Tanya B.
Frankel, Paul Henry
Li, Xiaochen
Pal, Sumanta Kumar
Tripathi, Abhishek
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA104 - LBA104
[6] Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
Ebrahimi, Hedyeh
Meza, Luis A.
Lee, Keehoon
Malhotra, Jasnoor
Alcantara, Marice
Zengin, Zeynep Busra
Dizman, Nazli
Govindarajan, Ameish
Hsu, Joann
Llamas-Quitiquit, Marian
Chawla, Neal Shiv
Castro, Daniela V.
Mercier, Benjamin D.
Liu, Sandy
Chehrazi-Raffle, Alex
Dorff, Tanya B.
Frankel, Paul Henry
Li, Xiaochen
Pal, Sumanta Kumar
Tripathi, Abhishek
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[7] Impact of microbiome modulation on serum cytokine profile in a randomized, phase I trial of cabozantinib/nivolumab (cabo/nivo) with or without CBM588 in pts with metastatic renal cell carcinoma (mRCC)
Li, Yu Jun
Ebrahimi, Hedyeh
Meza, Luis
Malhotra, Jasnoor
Li, Xiaochen
Dizman, Nazli
Dorff, Tanya
Frankel, Paul
Llamas-Quitiquit, Marian
Hsu, JoAnn
Zengin, Zeynep
Alcantara, Marice
Castro, Daniela
Mercier, Benjamin
Chawla, Neal
Chehrazi-Raffle, Alexander
Barragan-Carrillo, Regina
Gillece, John
Trent, Jeffrey
Lee, Peter
Parks, Thomas
Takahashi, Motomichi
Hayashi, Atsushi
Caporaso, J. Gregory
Lee, Keehoon
Tripathi, Abhishek
Pal, Sumanta
ONCOLOGIST, 2024, 29 : S36 - S37
[8] Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.
Dizman, Nazli
Meza, Luis A.
Bergerot, Paulo Gustavo
Dorff, Tanya B.
Lyou, Yung
Frankel, Paul Henry
Llamas, Marian
Hsu, Joann
Zengin, Zeynep Busra
Malhotra, Jasnoor
Govindarajan, Ameish
Castro, Daniela V.
Gillece, John D.
Reining, Lauren J.
Trent, Jeffrey M.
Takahashi, Motomichi
Oka, Kentaro
Higashi, Seiya
Highlander, Sarah K.
Pal, Sumanta K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC)
Agarwal, Anika
Modliszewski, Jennifer
Davey, Lauren
Reyes-Martinez, Marco
Runyambo, Daniella
Corcoran, David
Dressman, Holly
George, Daniel J.
Valdivia, Raphael
Armstrong, Andrew J.
Zhang, Tian
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[10] Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Martini, Dylan J.
Liu, Yuan
Shabto, Julie M.
Carthon, Bradley Curtis
Russler, Greta
Hitron, Elise
Caulfield, Sarah
Kissick, Haydn
Harris, Wayne
Kucuk, Omer
Master, Viraj A.
Bilen, Mehmet Asim
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →